Novel ED treatment enters clinical trials in Europe
UK-based speciality pharmaceuticals company Vectura has initiated patient screening and enrolment into a Phase Iia clinical study for its product VR 004 for the treatment of erectile dysfunction (ED).
UK-based speciality pharmaceuticals company Vectura has initiated patient screening and enrolment into a Phase Iia clinical study for its product VR 004 for the treatment of erectile dysfunction (ED).
The study will evaluate the profile of a number of dosage strengths of VR 004 in patients with mild to moderate ED.
The pharmaceutical compound formulated in VR 004 has been the subject of a number of published clinical trials, where efficacy and safety in ED have been confirmed. However, the Vectura study will be the first in which this compound has been delivered through the lungs. It is anticipated that this form of drug delivery will have a faster onset of action than drugs taken orally.
Vectura's ceo, Peter Virley, commented: 'This clinical trial is a significant milestone in our evolution from a technology-based to a products-based company. We are very excited about the prospects for VR 004, which has the potential to offer real clinical advantages in a large, rapidly growing market where not all patients' needs are currently well-served.'